Public Health in the Precision-Medicine Era
By Ronald Bayer, Ph.D. & Sandro Galea, M.D., Dr.P.H.,
New England Journal of Medicine
| 08. 06. 2015
Untitled Document
That clinical medicine has contributed enormously to our ability to treat and cure sick people is beyond contention. But whether and to what extent medical care has transformed morbidity and mortality patterns at a population level and what contribution, if any, it has made to the well-being and life expectancy of the least-advantaged people have been matters of contention for more than a century. This debate has taken on renewed importance as the scientific leadership at the National Institutes of Health (NIH), National Academy of Medicine, and U.S. universities have taken up the challenge of personalized or precision medicine. It is a challenge given all the more salience by President Barack Obama's announcement in his State of the Union address that his administration would seek to fund a major new initiative. Responding to the President's words, Harold Varmus, director of the National Cancer Institute, and Francis Collins, director of the NIH, have written that “What is needed now is a broad research program to build the evidence base needed to guide clinical practice.”1
The enthusiasm for this...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...